Haleon PLC Executes Share Buyback to Strengthen Market Position

Haleon PLC ( (GB:HLN) ) has provided an announcement.

Haleon PLC announced the purchase of 797,519 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction reflects the company’s strategic financial management, potentially enhancing shareholder value and consolidating its market position by reducing the number of shares with voting rights to 9,001,249,980.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s strong financial performance and bullish technical indicators are the primary drivers of the stock’s favorable score. The company’s strategic initiatives, including a share buyback program, further bolster its market position. However, the high P/E ratio and potential valuation concerns slightly temper the score.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company offers products across six major categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its portfolio includes renowned brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.

Average Trading Volume: 27,628,330

Technical Sentiment Signal: Buy

Current Market Cap: £37.26B

For an in-depth examination of HLN stock, go to TipRanks’ Stock Analysis page.